| Diabetes Mellitus
Fiasp vs Lantus
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Fiasp vs Lantus Solostar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLantus Solostar has a higher rate of injection site reactions vs Fiasp based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lantus Solostar but not Fiasp, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fiasp
Lantus Solostar
At A Glance
SC injection
With meals
Rapid-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.
Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.
Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.
Diabetes Mellitus, Type 1 Approximately one-third of total daily insulin requirements SC once daily at the same time each day; use short-acting, premeal insulin to satisfy the remainder.
Diabetes Mellitus, Type 2 0.2 units/kg or up to 10 units SC once daily for insulin-naive patients; adjust based on metabolic needs and glucose monitoring results.
Contraindications
- Episodes of hypoglycemia
- Known hypersensitivity to insulin aspart or any excipient in FIASP
- During episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in LANTUS
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)
Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain
Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site
Most common (>=5%) Upper respiratory tract infection, infection (body system unspecified), accidental injury, headache, peripheral edema, retinal vascular disorder, injection site reactions (redness, pain, itching, urticaria, edema, inflammation)
Serious Severe hypoglycemia, systemic hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock), hypokalemia, lipodystrophy, weight gain
Postmarketing Medication errors with rapid-acting insulins accidentally administered instead of LANTUS, localized cutaneous amyloidosis at injection site
Pharmacology
Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
Insulin glargine is a long-acting human insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, providing a relatively constant concentration/time profile over 24 hours with no pronounced peak after subcutaneous injection.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fiasp
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (9/12) · Qty limit (8/12)
Lantus Solostar
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Fiasp
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lantus Solostar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fiasp
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Lantus Solostar
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fiasp.
No savings programs available for Lantus Solostar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Lantus SolostarView full Lantus Solostar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.